| Andrew Lester C Chua, CRNA | |
|
4700 Las Vegas Blvd N, Nellis Afb, NV 89191-6600 | |
| (702) 653-3550 | |
| Not Available |
| Full Name | Andrew Lester C Chua |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 12 Years |
| Location | 4700 Las Vegas Blvd N, Nellis Afb, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235489279 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 26NR12812100 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Coast Plaza Hospital | Norwalk, CA | Hospital |
| Garfield Medical Center | Monterey park, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alliance Anesthesia Associates Inc | 8628318318 | 8 |
| Medvantage Anesthesia Care Inc | 8628350584 | 15 |
News Archive
We cordially invite you to attend Markers in Cancer, a joint meeting by ASCO, EORTC & NCI which will be held 7 - 9 November 2013 in Brussels.
Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.
Researchers from Genethon, the AFM-Telethon laboratory, Inserm (UMR 1089, Nantes) and the University of London (Royal Holloway) demonstrated the efficacy of an innovative gene therapy in the treatment of Duchenne muscular dystrophy.
An automated system that identifies high-risk osteoporosis patients being treated for fractures and can generate letters encouraging follow-up is an effective way to promote osteoporosis intervention and prevent future fractures, according to Penn State College of Medicine researchers.
Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance for its Amicus® separator with new wireless data-export capabilities.
› Verified 9 days ago
| Entity Name | Landmark Anesthesia Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770035024 PECOS PAC ID: 5698055804 Enrollment ID: O20161206000144 |
News Archive
We cordially invite you to attend Markers in Cancer, a joint meeting by ASCO, EORTC & NCI which will be held 7 - 9 November 2013 in Brussels.
Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.
Researchers from Genethon, the AFM-Telethon laboratory, Inserm (UMR 1089, Nantes) and the University of London (Royal Holloway) demonstrated the efficacy of an innovative gene therapy in the treatment of Duchenne muscular dystrophy.
An automated system that identifies high-risk osteoporosis patients being treated for fractures and can generate letters encouraging follow-up is an effective way to promote osteoporosis intervention and prevent future fractures, according to Penn State College of Medicine researchers.
Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance for its Amicus® separator with new wireless data-export capabilities.
› Verified 9 days ago
| Entity Name | Medvantage Anesthesia Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598110066 PECOS PAC ID: 8628350584 Enrollment ID: O20170130000748 |
News Archive
We cordially invite you to attend Markers in Cancer, a joint meeting by ASCO, EORTC & NCI which will be held 7 - 9 November 2013 in Brussels.
Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.
Researchers from Genethon, the AFM-Telethon laboratory, Inserm (UMR 1089, Nantes) and the University of London (Royal Holloway) demonstrated the efficacy of an innovative gene therapy in the treatment of Duchenne muscular dystrophy.
An automated system that identifies high-risk osteoporosis patients being treated for fractures and can generate letters encouraging follow-up is an effective way to promote osteoporosis intervention and prevent future fractures, according to Penn State College of Medicine researchers.
Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance for its Amicus® separator with new wireless data-export capabilities.
› Verified 9 days ago
| Entity Name | Alliance Anesthesia Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730667841 PECOS PAC ID: 8628318318 Enrollment ID: O20190315000626 |
News Archive
We cordially invite you to attend Markers in Cancer, a joint meeting by ASCO, EORTC & NCI which will be held 7 - 9 November 2013 in Brussels.
Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.
Researchers from Genethon, the AFM-Telethon laboratory, Inserm (UMR 1089, Nantes) and the University of London (Royal Holloway) demonstrated the efficacy of an innovative gene therapy in the treatment of Duchenne muscular dystrophy.
An automated system that identifies high-risk osteoporosis patients being treated for fractures and can generate letters encouraging follow-up is an effective way to promote osteoporosis intervention and prevent future fractures, according to Penn State College of Medicine researchers.
Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance for its Amicus® separator with new wireless data-export capabilities.
› Verified 9 days ago
| Entity Name | Trusted Anesthesia Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174143473 PECOS PAC ID: 4587095815 Enrollment ID: O20200520002451 |
News Archive
We cordially invite you to attend Markers in Cancer, a joint meeting by ASCO, EORTC & NCI which will be held 7 - 9 November 2013 in Brussels.
Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.
Researchers from Genethon, the AFM-Telethon laboratory, Inserm (UMR 1089, Nantes) and the University of London (Royal Holloway) demonstrated the efficacy of an innovative gene therapy in the treatment of Duchenne muscular dystrophy.
An automated system that identifies high-risk osteoporosis patients being treated for fractures and can generate letters encouraging follow-up is an effective way to promote osteoporosis intervention and prevent future fractures, according to Penn State College of Medicine researchers.
Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance for its Amicus® separator with new wireless data-export capabilities.
› Verified 9 days ago
| Entity Name | Hypnos Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295449866 PECOS PAC ID: 9234583402 Enrollment ID: O20230922000468 |
News Archive
We cordially invite you to attend Markers in Cancer, a joint meeting by ASCO, EORTC & NCI which will be held 7 - 9 November 2013 in Brussels.
Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.
Researchers from Genethon, the AFM-Telethon laboratory, Inserm (UMR 1089, Nantes) and the University of London (Royal Holloway) demonstrated the efficacy of an innovative gene therapy in the treatment of Duchenne muscular dystrophy.
An automated system that identifies high-risk osteoporosis patients being treated for fractures and can generate letters encouraging follow-up is an effective way to promote osteoporosis intervention and prevent future fractures, according to Penn State College of Medicine researchers.
Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance for its Amicus® separator with new wireless data-export capabilities.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Andrew Lester C Chua, CRNA 4700 Las Vegas Blvd N, Nellis Afb, NV 89191-6600 Ph: (702) 653-3550 | Andrew Lester C Chua, CRNA 4700 Las Vegas Blvd N, Nellis Afb, NV 89191-6600 Ph: (702) 653-3550 |
News Archive
We cordially invite you to attend Markers in Cancer, a joint meeting by ASCO, EORTC & NCI which will be held 7 - 9 November 2013 in Brussels.
Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.
Researchers from Genethon, the AFM-Telethon laboratory, Inserm (UMR 1089, Nantes) and the University of London (Royal Holloway) demonstrated the efficacy of an innovative gene therapy in the treatment of Duchenne muscular dystrophy.
An automated system that identifies high-risk osteoporosis patients being treated for fractures and can generate letters encouraging follow-up is an effective way to promote osteoporosis intervention and prevent future fractures, according to Penn State College of Medicine researchers.
Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance for its Amicus® separator with new wireless data-export capabilities.
› Verified 9 days ago
Dr. Kenneth Narayan, DNP, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4700 Las Vegas Blvd N, Nellis Afb, NV 89191 Phone: 702-653-2273 | |
Steven M Sertich, C.R.N.A. Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 4700 Las Vegas Blvd N, Nellis Afb, NV 89191 Phone: 702-653-2392 | |
William N Clark, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 4700 Las Vegas Blvd N, Nellis Afb, NV 89191 Phone: 702-653-3550 | |
Joshua William Boyle, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 4700 Las Vegas Blvd N, Nellis Afb, NV 89191 Phone: 702-653-3550 | |
Ms. Joanne K Heins, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4700 Las Vegas Blvd N, Nellis Afb, NV 89191 Phone: 702-653-3526 | |
Girah Diveka Caraballo, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 4700 Las Vegas Blvd N, Nellis Afb, NV 89191 Phone: 702-653-2273 |